MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ
0.6630
-0.0365
-5.22%
Opening 12:44 04/12 EDT
OPEN
0.6980
PREV CLOSE
0.6995
HIGH
0.6980
LOW
0.6612
VOLUME
30.43K
TURNOVER
0
52 WEEK HIGH
12.27
52 WEEK LOW
0.5000
MARKET CAP
3.04M
P/E (TTM)
-0.1276
1D
5D
1M
3M
1Y
5Y
PHIO PHARMACEUTICALS ANNOUNCES UPCOMING PRESENTATION AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF CELL AND GENE THERAPY (ASCGT)
Reuters · 1d ago
Weekly Report: what happened at PHIO last week (0401-0405)?
Weekly Report · 4d ago
National Spotlight Features Phio’s Innovative RNAi Technology Platform
Program will be airing on PBS with Dennis Quaid in April. INTASYL platform will be the focus of Viewpoint. The program will air in April on PBS stations across the country. It will also be seen on Fox Business Network. Phio Pharmaceuticals Corp. Is a clinical stage biotechnology company.
Barchart · 04/03 06:30
Phio Pharmaceuticals on the Brink: Nasdaq Delisting Looms Over Falling Stock Prices
TipRanks · 04/03 06:01
PHIO Stock Earnings: Phio Pharma Beats EPS for Q4 2023
Phio Pharma reported earnings per share of -17 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. Phio Pharma's results were above the analyst estimate for EPS of -$1.30. The company just reported results for fourth quarter.
Investorplace · 04/02 15:52
Phio Pharmaceuticals GAAP EPS of -$5.20
Phio Pharmaceuticals Corp. Reports FY GAAP EPS of -$5.20. At December 31, 2023 we had cash of $8.5 million as compared to $11.8 million at the end of 2022. The company is expected to report quarterly earnings of $0.02 per share.
Seeking Alpha · 04/02 11:39
*Phio Pharmaceuticals 2023 Loss/Shr $5.20 >PHIO
Dow Jones · 04/02 11:36
PHIO PHARMACEUTICALS REPORTS 2023 YEAR END FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Reuters · 04/02 11:30
More
About PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. Its INTASYL compounds are designed to precisely target specific proteins that reduce the body’s ability to fight cancer without the need for specialized formulations or drug delivery systems, and are designed to make immune cells effective in killing tumor cells. Its lead product candidate, PH-762, is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. Its second product candidate, PH-894, is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby effecting the immune system as well as the tumor.

Webull offers Phio Pharmaceuticals Corp stock information, including NASDAQ: PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHIO stock methods without spending real money on the virtual paper trading platform.